These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27216947)

  • 41. PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.
    Buonaiuto G; De Mori V; Braus A; Balini A; Berzi D; Carpinteri R; Forloni F; Meregalli G; Ronco GL; Bossi AC
    BMJ Open Diabetes Res Care; 2016; 4(1):e000216. PubMed ID: 27486519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.
    Wharton S; Haase CL; Kamran E; Liu A; Mancini J; Neish D; Pakseresht A; Power GS; Christensen RA
    Obes Sci Pract; 2020 Aug; 6(4):382-389. PubMed ID: 32874673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corrigendum: Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: a real-world comparative cohort study.
    Liao YN; Chen HY; Yang CW; Lee PW; Hsu CY; Huang YT; Yang TH
    Front Pharmacol; 2023; 14():1222106. PubMed ID: 37288108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in the treatment of type 2 diabetes: impact of dulaglutide.
    Thompson AM; Trujillo JM
    Diabetes Metab Syndr Obes; 2016; 9():125-36. PubMed ID: 27217788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
    J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Vanderheiden A; Harrison L; Warshauer J; Li X; Adams-Huet B; Lingvay I
    JAMA Intern Med; 2016 Jul; 176(7):939-47. PubMed ID: 27273731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
    Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
    Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
    Cahn A; Raz I; Mosenzon O; Leibowitz G; Yanuv I; Rozenberg A; Iqbal N; Hirshberg B; Sjostrand M; Stahre C; Im K; Kanevsky E; Scirica BM; Bhatt DL; Braunwald E
    Diabetes Care; 2016 Aug; 39(8):1329-37. PubMed ID: 27222508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.
    Standl E; Schnell O; McGuire DK
    Circ Res; 2016 May; 118(11):1830-43. PubMed ID: 27230644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.
    Rutten GE; Tack CJ; Pieber TR; Comlekci A; Ørsted DD; Baeres FM; Marso SP; Buse JB;
    Diabetol Metab Syndr; 2016; 8():37. PubMed ID: 27274772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
    Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
    Nauck M; Rizzo M; Johnson A; Bosch-Traberg H; Madsen J; Cariou B
    Diabetes Care; 2016 Sep; 39(9):1501-9. PubMed ID: 27311491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.
    Gorgojo-Martínez JJ; Feo-Ortega G; Serrano-Moreno C
    Surg Obes Relat Dis; 2016 Dec; 12(10):1856-1863. PubMed ID: 27256860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
    Davies ML; Pham DQ; Drab SR
    Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.